Program
vamorolone
Also written as “Vamorolone”, “Vamorolone 0.25 mg/day/day” and “Vamorolone 0.75 mg/day/day”.
Its studies are mostly in Muscular Dystrophy, Duchenne, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ReveraGen BioPharma | 70 open or running | phase 2since Apr 28, 2016 | Mar 2, 2015 | none ahead |
| Santhera Pharmaceuticals | 41 open or running | phase 4since Nov 16, 2024 | Nov 9, 2021 | Sep 2028phase 4 · NCT06713135 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 2, 2015First study: phase 1 study in HealthyNew to ReveraGen BioPharmaReveraGen BioPharma · NCT02415439 · 86 enrolled · United States
- Apr 28, 20162 phase 2 studies in Muscular Dystrophy, DuchenneReveraGen BioPharma · NCT02760277, NCT02760264
- Jan 30, 2017Phase 2 study in Muscular Dystrophy, DuchenneReveraGen BioPharma · NCT03038399 · 46 enrolled · United States, Australia, Canada and more
- Jan 9, 2018Phase 2 study in Muscular Dystrophy, DuchenneReveraGen BioPharma · NCT03439670 · 121 enrolled · United States, Australia, Belgium and more
- Apr 13, 2020Phase 2 study in Pediatric ulcerative colitisReveraGen BioPharma · NCT04348890
- Nov 9, 2021Santhera Pharmaceuticals's first study: phase 2 study in Muscular Dystrophy, DuchenneNew to Santhera PharmaceuticalsSanthera Pharmaceuticals · NCT05185622 · 54 enrolled · Canada
- Dec 8, 2021Phase 2 study in Muscular Dystrophy, DuchenneReveraGen BioPharma · NCT05166109 · 46 enrolled · United States, Italy
- Sep 5, 20242 phase 1 studiesSanthera Pharmaceuticals · NCT06689527, NCT06649409
- Nov 16, 2024Phase 4 study in Muscular Dystrophy, DuchenneSanthera Pharmaceuticals · NCT06713135 · 80 enrolled · Belgium, Czechia, Greece and more
Ahead
- Sep 2028Primary completion: phase 4 study in Muscular Dystrophy, DuchenneSanthera Pharmaceuticals · NCT06713135
TargetBeta
“Glucocorticoid receptor agonist; Mineralocorticoid receptor antagonist”ChEMBL 37, by rule
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06713135Muscular Dystrophy, Duchenne · Belgium, Czechia, Greece and more | 4 | Active, not recruiting | Santhera Pharmaceuticals | Sep 2028 | 80 |
| NCT06689527Drug Interaction · Germany | 1 | Completed | Santhera Pharmaceuticals | Sep 24, 2024 | 18 |
| NCT06649409Pharmacodynamic · Germany | 1 | Completed | Santhera Pharmaceuticals | Jun 29, 2024 | 30 |
| NCT05166109Muscular Dystrophy, Duchenne · United States, Italy | 2 | Completed | ReveraGen BioPharma | Aug 18, 2025 | 46 |
| NCT05185622Muscular Dystrophy, Duchenne · Canada | 2 | Completed | Santhera Pharmaceuticals | Jul 16, 2024 | 54 |
| NCT04348890Pediatric ulcerative colitis | 2 | Withdrawn | ReveraGen BioPharma | Sep 1, 2022 | 0 |
| NCT03439670Muscular Dystrophy, Duchenne · United States, Australia, Belgium and more | 2 | Completed | ReveraGen BioPharma | Feb 23, 2021 | 121 |
| NCT03038399Muscular Dystrophy, Duchenne · United States, Australia, Canada and more | 2 | Completed | ReveraGen BioPharma | Apr 30, 2020 | 46 |
| NCT02760277Muscular Dystrophy, Duchenne · United States, Australia, Canada and more | 2 | Completed | ReveraGen BioPharma | Apr 26, 2018 | 48 |
| NCT02760264Muscular Dystrophy, Duchenne · United States, Australia, Canada and more | 2 | Completed | ReveraGen BioPharma | May 1, 2018 | 48 |
| NCT02415439Healthy · United States | 1 | Completed | ReveraGen BioPharma | Nov 2015 | 86 |
How it is read
Names in the registry
- “Vamorolone”, 8 entries
- “Vamorolone 0.25 mg/day/day”, 2 entries
- “Vamorolone 0.75 mg/day/day”, 2 entries
- “Vamorolone 2.0 mg/day/day”, 2 entries
- “Vamorolone 6.0 mg/day/day”, 2 entries
Conditions, from the studies’ own filings
- Muscular Dystrophy, Duchenne, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.